Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03055832 · ClinicalTrials.gov registry record · NA

Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

A NA study of Meibomian Gland Dysfunction, sponsored by Tear Film Innovations.

Completed
Registry status
NA
Development phase
142
Enrollment target
7
Study locations

NCT03055832 is a NA study of Meibomian Gland Dysfunction that has completed, run by Tear Film Innovations. The registered enrollment target is 142 participants, above the 85-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (67% higher). The trial reports 7 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03055832, a NA study of Meibomian Gland Dysfunction, has completed, sponsored by Tear Film Innovations.

COMPLETED
Registry status
NA
Development phase
142 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal Pulsation System.

Conditions Studied

Meibomian Gland Dysfunction

Interventions

  • DEVICE iLux 2020 System
  • DEVICE LipiFlow Pulsation System

Study Locations (7)

Arizona

  • TearFilm Investigative Site - Phoenix
  • TearFilm Investigative Site - Scottsdale

Colorado

  • TearFilm Investigative Site - Centennial
  • TearFilm Investigative Site - Greenwood Village

Missouri

  • TearFilm Investigative Site - Chesterfield
  • TearFilm Investigative Site - Kansas City

California

  • TearFilm Investigative Site - San Diego

Trial Details

FieldValue
Enrollment Target 142 participants
Start Date 2017-02-09
Est. Completion 2017-07-20
Phase NA

Sponsor

Tear Film Innovations

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03055832

The ClinicalTrials.gov registry entry for NCT03055832 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (67% higher). The listed sponsor is Tear Film Innovations, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which iLux 2020 System is the first listed.

NCT03055832 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Colorado, Missouri.

Frequently Asked Questions

What is clinical trial NCT03055832 about?

NCT03055832 is a clinical study titled "Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction". The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal Pulsation System.

What is the current status of trial NCT03055832?

This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2017-02-09. Estimated completion is 2017-07-20.

What conditions does trial NCT03055832 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction.

What interventions are being tested in trial NCT03055832?

The interventions under investigation include: iLux 2020 System (DEVICE), LipiFlow Pulsation System (DEVICE).

Who is sponsoring clinical trial NCT03055832?

This trial is sponsored by Tear Film Innovations, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03055832 being conducted?

This trial has 7 study locations across Arizona, California, Colorado, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Meibomian Gland Dysfunction

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.